Copeptin and decline in kidney function

American Journal of Nephrology

Volumn 44, Issue 1, 2016, Pages 19-21

  Yan, Jingyin ^a   Navaneethan, Sankar D ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ARGIPRESSIN; COPEPTIN; VASOPRESSIN V2 RECEPTOR; BIOLOGICAL MARKER; GLYCOPEPTIDE;

ALBUMINURIA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HORMONE BLOOD LEVEL; HUMAN; KIDNEY CYST; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK; SUDDEN CARDIAC DEATH; CHRONIC KIDNEY FAILURE;

ARGININE VASOPRESSIN; BIOMARKERS; GLYCOPEPTIDES; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84976579574     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000447369     Document Type: Review

References (10)

1. Bankir L, Bouby N, Ritz E: Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol 2013; 9: 223-239.
2. Morgenthaler NG, Struck J, Jochberger S, Dunser MW: Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19: 43-49.
3. Fenske W, Wanner C, Allolio B, Drechsler C, Blouin K, Lilienthal J, Krane V: Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J AM Soc Nephrol 2011; 22: 782-790.
4. Tasevska I, Enhorning S, Persson M, Nilsson PM, Melander O: Increased levels of copeptin, a surrogate marker of AVP, are associated with an increased risk of CKD in a healthy population. Am J Nephrol 2016; 44:22-28.
5. Roussel R, Matallah N, Bouby N, El Boustany R, Potier L, Fumeron F, Mohammedi K, Balkau B, Marre M, Bankir L, Velho G: Plasma copeptin and decline in renal function in a cohort from the community: the prospective D.E.S.I.R. study. Am J Nephrol 2015; 42: 107-114.
6. Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT: Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 2010; 77: 29-36.
7. Enhorning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM, Melander O: Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmo diet and cancer study cardiovascular cohort. Int J Obes (Lond) 2013; 37: 598-603.
8. Boertien WE, Riphagen IJ, Drion I, Alkhalaf A, Bakker SJ, Groenier KH, Struck J, de Jong PE, Bilo HJ, Kleefstra N, Gansevoort RT: Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia 2013; 56: 1680-1688.
9. Okada T, Sakaguchi T, Hatamura I, Saji F, Negi S, Otani H, Muragaki Y, Kawachi H, Shigematsu T: Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. Clin Exp Nephrol 2009; 13: 438-446.
10. Sontrop JM, Huang SH, Garg AX, Moist L, House AA, Gallo K, Clark WF: Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial. BMJ Open 2015; 5:e008634.